Holen Sie sich die Stockscreener-App
67.36
1.71%
-1.17
Handel nachbörslich:
67.36
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration - simplywall.st
Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth? - Sahm
Summit Global Investments Buys New Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BMRN vs. ILMN: Which Stock Is the Better Value Option? - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Yahoo Finance
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth - MarketBeat
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High? - Yahoo Finance
BMRN: Strong Q2 growth, Amicus integration, and pipeline expansion position for sustained revenue gains - TradingView
Transcript : BioMarin Pharmaceutical Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-12-2026 08 - marketscreener.com
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Janus Henderson Multi-Sector Income Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD By Investing.com - Investing.com Nigeria
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week High on Analyst Upgrade - MarketBeat
Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD - Investing.com
BioMarin presentation to stream live from Boston on Aug. 12 - Stock Titan
BMRN Maintained by Canaccord Genuity -- Price Target Raised to $114 - GuruFocus
Canaccord raises BioMarin stock price target on revenue growth By Investing.com - Investing.com Australia
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $114.00 at Canaccord Genuity Group - MarketBeat
BioMarin scraps BMN 401, ending its $270 million Inozyme bet - The Pharma Letter
Canaccord raises BioMarin stock price target on revenue growth - Investing.com India
BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication - biospace.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unveiling a 40% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
BioMarin Pharmaceutical Inc. (BMRN) options chain - Yahoo Finance Australia
Pacer Advisors Inc. Sells 913,713 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin (BMRN) Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum - Sahm
BioMarin Pharmaceutical Inc. (BMRN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
BioMarin Earnings: Voxzogo Resilience and Amicus Strength Support Positive Outlook - Morningstar
Oppenheimer raises BioMarin stock price target on strong quarter By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside - TradingView
Biomarin Pharmaceutical Inc (BM8.SG) stock price, news, quote and history - Yahoo Finance UK
Morgan Stanley Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
BioMarin bins rare disease asset from Inozyme acquisition - FirstWord PHARMA
BioMarin Pharmaceutical Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BMRN) 2026-08-07 - Seeking Alpha
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised - Yahoo Finance
BioMarin Lifts 2026 Outlook on Strong Voxzogo Sales, Wedbush Says - Yahoo Finance
HC Wainwright Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Oppenheimer Adjusts PT on BioMarin Pharmaceutical to $97 From $95, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises BioMarin stock price target on strong quarter - Investing.com
Earnings call transcript: BioMarin Q2 2026 beats forecasts, lifts outlook By Investing.com - Investing.com Nigeria
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results - MarketBeat
BioMarin (BMRN) Stock May Be Above Fair Value After ReNU Therapy Deal - Yahoo Finance
BioMarin Pharmaceutical Inc (BMRN) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance
Earnings call transcript: BioMarin Q2 2026 beats forecasts, lifts outlook - Investing.com
BioMarin Pharmaceutical Q2 Earnings Call Highlights - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance - MarketBeat
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
BMRN: Q2 revenue up 20% to nearly $1B; guidance raised as key brands approach blockbuster status - TradingView
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
BioMarin Pharmaceutical Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.90$5.10, vs. FactSet Est of $4.94 - marketscreener.com
BioMarin Pharmaceutical Q2 Non-GAAP Earnings Fall, Revenue Rises; Lifts 2026 Guidance - marketscreener.com
BioMarin Pharmaceutical 2Q 2026: Revenue $989.7M, EPS $0.23— 10-Q Summary - TradingView
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):